Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia

Leuk Lymphoma. 2017 Jun;58(6):1506-1508. doi: 10.1080/10428194.2016.1233541. Epub 2016 Oct 10.

Affiliations

¹ a Department of Clinical Therapeutics , Alexandra Hospital, National and Kapodistrian University of Athens , Athens , Greece.
² b Laikon Hospital , National and Kapodistrian University of Athens , Athens , Greece.
³ c Evaggelismos General Hospital , Athens , Greece.

PMID: 27724158
DOI: 10.1080/10428194.2016.1233541

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / administration & dosage
Drug Resistance, Neoplasm
Humans
Recurrence
Retreatment
Survival Analysis
Treatment Outcome
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives
Waldenstrom Macroglobulinemia / drug therapy*
Waldenstrom Macroglobulinemia / mortality
Waldenstrom Macroglobulinemia / pathology*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cyclophosphamide
Vidarabine
ofatumumab
fludarabine